SpyGlass Pharma Inc (SGP) is a clinical-stage ophthalmic pharmaceutical company developing sustained-release drug-device combination products for chronic eye diseases. The company has generated no product revenue as of December 31, 2025, and has funded operations entirely through private equity financings, including a $77.3 million Series D raise in May and June 2025 and a $50.0 million Series C-2 raise in March 2025. Net losses were $39.9 million for the year ended December 31, 2025 and $29.2 million for the year ended December 31, 2024, with an accumulated deficit of $104.7 million as of December 31, 2025. The lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is a drug-device combination intraocular lens designed to deliver three years of sustained bimatoprost release during routine cataract surgery. Two registrational Phase 3 clinical trials were recently initiated, with enrollment expected to complete in 2027 and a 505(b)(2) NDA submission planned for 2028. Co-founders Malik Y. Kahook, M.D. and Glenn Sussman have collaborated on ophthalmic products for over two decades.

Revenue model

SpyGlass Pharma has generated no product revenue. Operations have been funded through private placements of common stock and redeemable convertible preferred stock. Future revenue, if any, would depend on regulatory approval and commercialization of product candidates, anticipated through a buy-and-bill reimbursement model in ophthalmology.

Products and services

Lead candidate: BIM-IOL System, a drug-led drug-device combination intraocular lens delivering sustained bimatoprost for open-angle glaucoma (OAG) or ocular hypertension (OHT), targeting Phase 3 enrollment completion in 2027 and NDA submission in 2028. Second candidate: BIM-DRS (Drug Ring System), a non-bioerodible ring-shaped sustained-release implant delivering bimatoprost for at least three years, with first-in-human trials planned for 2026. Early-stage pipeline includes SPY-004 (small molecule for AMD), ophthalmic steroid and NSAID delivery for postoperative care, and programs for chronic uveitis. The company retains exclusive worldwide rights to all programs.

Customers and end markets

Target end users are cataract surgeons treating patients with OAG or OHT. The BIM-IOL System is designed to integrate into routine cataract surgery workflows without specialized MIGS training. End markets include glaucoma management and cataract surgery, with secondary programs targeting age-related macular degeneration, postoperative eye care, and chronic uveitis.

Value-chain role

SpyGlass Pharma is a drug-device combination product developer operating at the R&D and clinical-stage level. The company designs and develops sustained-release ophthalmic implant platforms and plans to commercialize approved products through procedural and buy-and-bill reimbursement channels. Reimbursement would occur through Medicare, Medicaid, and private payors.

Geographic exposure

The company holds exclusive worldwide development and commercialization rights to its programs. The filing does not specify current commercial geographic operations, as no products are approved or marketed as of the filing date (2026-03-26).

Source: SEC 10-K, filed 2026-03-26

Industry: Surgical & Medical Instruments & Apparatus